Physicians' Academy for Cardiovascular Education

Two meta-analyses support prioritizing use of SGLT2i in all HF patients

News - Aug. 27, 2022

A pre-specified meta-analysis of DELIVER and EMPEROR-Preserved

Presented at the ESC congress 2022 by: Muthiah Vaduganathan, MD – Boston, MA, USA

Introduction and methods

Two meta-analyses were performed with data of large outcome trials with SGLT2 inhibitors.

Main results

DELIVER and EMPEROR-Preserved meta-analysis

Meta-analysis of 5 large SGLT2i trials in HF


The first prespecified meta-analysis of the 2 large trials DELIVER and EMPEROR-Preserved that enrolled patients with HFmrEF and HFpEF confirmed that SGLT2 inhibitors reduce CV death or HF hospitalization in this patient population.

Furthermore, a second comprehensive meta-analysis of 5 large outcomes trials with SGLT2 inhibitors with >20.000 participants with HF showed that SGLT2 inhibitors reduce CV outcomes and all-cause death across a broad range of patients with HF.

Share this page with your colleagues and friends: